Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To compare the efficacy and safety of the combination of alogliptin and actoplus met with that of actoplus met alone in improving the glucose and lipid metabolism and pancreatic function in T2DM patients complicated with MAFLD.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| alogliptin and actoplus met | Experimental |
| |
| actoplus met | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| alogliptin and actoplus met | Drug | combination of alogliptin and actoplus met |
|
| Measure | Description | Time Frame |
|---|---|---|
| hemoglobin A1c | 6 months of treatment |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| actoplus met | Drug | actoplus met |
|
| ID | Term |
|---|---|
| C520853 | alogliptin |
Not provided
Not provided
Not provided